Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CANN001
- Development stage
- Unknown
- Lead developer
- Cannenta
- Modality
- Small Molecules, Hydrogel Systems → Drug Delivery Systems
- Administration
- Topical
01
Overview
CANN001 is an investigational topical hydrogel wound dressing containing 0.3% 2-deoxy-D-ribose (2dDR), a small ribose-derived sugar. Developed by Cannenta in collaboration with the University of Western Australia, CANN001 is designed to promote wound healing by stimulating angiogenesis (the formation of new blood vessels) and upregulating the local expression of vascular endothelial growth factor (VEGF). It is being evaluated in a Phase 1 clinical trial for the treatment of diabetic foot ulcers (DFUs).
- Other names
- 2-deoxy-D-ribose hydrogel2-deoxy-D-ribose hydrogel dressing2dDR hydrogel
02
Targets
VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on CANN001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CANN001.